Author(s)

Mingqi Du, Zhixian Xu

Corresponding Author

Mingqi Du

ABSTRACT

In recent years, the biomedical industry has gradually become the focus of global competition. In particular, the outbreak of the COVID-19 in 2019 has made this industry a huge impact. The development of the entire industry today is affected by product and industry characteristics and a lot of uncertainty due to the epidemic. Therefore, it is more important to explore the performance level of today's listed companies in the biomedical industry and the future development direction. Based on this, this article will take the 2016-2020 annual report data of Fosun Pharma as a representative, use SPSS20 to perform time-series principal component analysis on the data, and use finance, operating ability, development potential, and product management as four subsystems. And then expand to 13 secondary indicators, trying to build a relatively complete and scientific performance evaluation system to comprehensively evaluate and analyze Fosun Pharma's performance. This survey shows that under the influence of COVID-19 in 2019, financial capabilities, operational capabilities, and development capabilities have all stagnated. After 19 years, financial and operational capabilities have recovered, and product management capabilities and development capabilities have shown a downward trend. It can be concluded that leading companies have a strong ability to respond to crises, but they should actively seek out the source of obstacles to development and continue to pay attention to whether their products will improve as the epidemic situation eases or need new production directions. The government should also actively introduce corresponding policies to help ease pressure on the industry.

KEYWORDS

Fosun Pharma, corporate performance analysis, time-series principal component analysis